1. Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study
- Author
-
Muñoz- Martínez, Sergio, Sapena, Victor, Forner, Alejandro, Bruix, Jordi, Sanduzzi-Zamparelli, Marco, Ríos, José, Bouattour, Mohamed, El Kassas, Mohamed, Guedes Leal, Cassia Regina, Mocan, Tudor, Nault, Jean-Charles, Camargo Pinheiro Alves, Rogerio, Reeves, Helen L., da Fonseca, Leonardo, García-Juárez, Ignacio, Pinato, David J., Varela, María, Alqahtani, Saleh A., Alvares-da-Silva, Mario Reis, Bandi, Juan C., Rimassa, Lorenza, Lozano, Mar, González Santiago, Jesús M., Tacke, Frank, Sala, Margarita, Anders, Maria Margarita, Lachenmayer, Anja, Piñero, Federico, França, Alex, Guarino, María, Elvevi, Alessandra, Cabibbo, Giuseppe, Peck-Radosavljevic, Markus, Rojas, Ángela, Vergara, Mercedes, Braconi, Chiara, Pascual, Sonia, Perelló, Christie, Mello, Vivianne, Rodríguez-Lope, Carlos, Acevedo, Juan, Villani, Rosanna, Hollande, Clemence, Vilgrain, Valérie, Tawheed, Ahmed, Ferguson Theodoro, Carmem, Sparchez, Zeno, Blaise, Lorraine, Viera-Alves, Daniele E., Watson, Robyn, Carrilho, Flair J., Moctezuma-Velázquez, Carlos, D'Alessio, Antonio, Iavarone, Massimo, Reig, María, Ministerio de Sanidad (España), European Association for the Study of the Liver, Cancer Treatment and Research Trust, Wellcome Trust, Cancer Research UK, Instituto de Salud Carlos III, Bristol Myers Squibb Foundation, Muñoz- Martínez, Sergio [0000-0003-0663-0575], Sapena, Victor [0000-0003-4379-6486], Forner, Alejandro [0000-0002-9014-4950], Ríos, José [0000-0002-0716-8784], González Santiago, Jesús M. [0000-0003-4667-4492], Rojas, Ángela [0000-0003-0853-4800], Hollande, Clemence [0000-0002-2287-0635], Muñoz- Martínez, Sergio, Sapena, Victor, Forner, Alejandro, Ríos, José, González Santiago, Jesús M., Rojas, Ángela, Hollande, Clemence, and Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, Jordi Bruix, Marco Sanduzzi-Zamparelli, José Ríos, Mohamed Bouattour, Mohamed El-Kassas, Cassia R. G. Leal, Tudor Mocan, Jean-Charles Nault, Rogerio C. P. Alves, Helen L. Reeves, Leonardo da Fonseca, Ignacio García-Juárez, David J. Pinato, María Varela, Saleh A. Alqahtani, Mario R. Alvares-da-Silva, Juan C. Bandi, Lorenza Rimassa, Mar Lozano, Jesús M. González Santiago, Frank Tacke, Margarita Sala, María Anders, Anja Lachenmayer, Federico Piñero, Alex França, Maria Guarino, Alessandra Elvevi, Giuseppe Cabibbo, Markus Peck-Radosavljevic, Ángela Rojas, Mercedes Vergara, Chiara Braconi, Sonia Pascual, Christie Perelló, Vivianne Mello, Carlos Rodríguez-Lope, Juan Acevedo, Rosanna Villani, Clemence Hollande, Valérie Vilgrain, Ahmed Tawheed, Carmem Ferguson Theodoro, Zeno Sparchez, Lorraine Blaise, Daniele E. Viera-Alves, Robyn Watson, Flair J. Carrilho, Carlos Moctezuma-Velázquez, Antonio D'Alessio, Massimo Iavarone, Maria Reig
- Subjects
Settore MED/12 - Gastroenterologia ,Carcinoma, Hepatocellular ,Hepatology ,Hepatocellular carcinoma ,SARS-CoV-2 ,Liver Neoplasms ,COVID-19 ,hepatocellular carcinoma ,mortality ,Cohort Studies ,liver cancer ,COVID-19 Testing ,Cross-Sectional Studies ,Humans ,Mortality ,Liver cancer ,Retrospective Studies - Abstract
Background & Aims Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84–11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24–12.74], 11.76% [95% CI 4.73–22.30], 20.69% [95% CI 11.35–31.96] and 34.52% [95% CI 17.03–52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49–4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29–7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. Conclusions This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period., Spanish Health Ministry; Ricerca Corrente, Grant/Award Number: RC2019/105-01, RC2018/105-01 and RC2017/105-01; European Association for the Study of the Liver (Andrew Burroughs Fellowship); Cancer Treatment and Research Trust (CTRT); Wellcome Trust Strategic Fund, Grant/Award Number: PS3416; Cancer Research UK (CR UK) centre, Grant/Award Number: C9380/A26813, C18342/A23390 and C9380/A18084; Instituto de Salud Carlos III, Grant/Award Number: PI18/0358, PI15/00145, CD18/00126, PI19/00819, FI19/00222, 16-0026, PI044031, PI18/00768, PI18/00542 and PI13/01229; Bristol Myers Squibb and Celgene; Cancer Research UK, Grant/Award Number: RCCPDB-Nov21/100008
- Published
- 2022